Deregulation of apoptosis is common in cancer and is often caused by overexpression of anti-apoptotic proteins in tumour cells. One important regulator of apoptosis is the cellular FLICE-inhibitory protein (c-FLIP), which is overexpressed, for example, in melanoma and Hodgkin's lymphoma cells. Here, we addressed the question whether deregulated c-FLIP expression in urothelial carcinoma impinges on the ability of death ligands to induce apoptosis. In particular, we investigated the role of the c-FLIP splice variants c-FLIP long (c-FLIP L ) and c-FLIP short (c-FLIP S ), which can have opposing functions. We observed diminished expression of the c-FLIP L isoform in urothelial carcinoma tissues as well as in established carcinoma cell lines compared with normal urothelial tissues and cells, whereas c-FLIP S was unchanged. Overexpression and RNA interference studies in urothelial cell lines nevertheless demonstrated that c-FLIP remained a crucial factor conferring resistance towards induction of apoptosis by death ligands CD95L and TRAIL. Isoform-specific RNA interference showed c-FLIP L to be of particular importance. Thus, urothelial carcinoma cells appear to fine-tune c-FLIP expression to a level sufficient for protection against activation of apoptosis by the extrinsic pathway. Therefore, targeting c-FLIP, and especially the c-FLIP L isoform, may facilitate apoptosis-based therapies of bladder cancer in otherwise resistant tumours.
Apoptosis is a controlled form of cell death, which is essential for normal development and the maintenance of tissue homeostasis in multicellular organisms. Deregulation of apoptosis disturbs the balance between the proliferation and death of cells, with too much proliferation leading to tumour formation and cancer. 1 Upregulation of anti-apoptotic cellular FLICE inhibitory proteins (c-FLIPs) have been demonstrated in different types of cancer. 2 Several mRNA isoforms of c-FLIP have been reported, from which three protein isoforms are expressed, namely c-FLIP long (c-FLIP L ), c-FLIP short (c-FLIP S ) and c-FLIP Raji (c-FLIP R ). [3] [4] [5] c-FLIP L resembles procaspase-8 with two death effector domains (DEDs) and a catalytically inactive caspase-like domain. The two shorter isoforms, c-FLIP S and c-FLIP R , mainly consist of the DEDs with a truncated C-terminal end. Interestingly, a functional single nucleotide polymorphism (SNP) regulates whether c-FLIP S or FLIP R is produced in humans. 6 The FLIP proteins can modulate apoptosis in close proximity to death receptors such as CD95 (Fas/Apo-1), tumour necrosis factor (TNF) receptor-1 (TNF-R1), TNF-related apoptosis inducing ligand (TRAIL) receptor-1 (TRAIL-R1; DR4) and TRAIL-R2 (DR5). 7 The so called death-inducing signalling complex (DISC) is formed upon triggering of death receptors and thereby activation of their intracellular domains, which allows recruitment of an adaptor protein such as FADD (Fasassociated death domain-containing protein), which, in turn, can recruit the DED-containing proteins procaspase-8, procaspase-10 and the different c-FLIP isoforms. 7 The initiator caspases 8 and 10 become activated upon dimerisation and proteolytic cleavage at the DISC, initiating a signalling cascade resulting in apoptosis. [8] [9] [10] The DEDs of c-FLIP allow recruitment to the DISC, 11 where cleavage of initiator caspases can be prevented and caspase activation is consequently inhibited. 3, 5, 12 Although the short isoforms c-FLIP S and c-FLIP R have been shown to solely possess anti-apoptotic functions, 5, 11, 12 the role of c-FLIP L has been more controversially discussed.
3,13 c-FLIP L was shown to exert either proapoptotic or anti-apoptotic functions depending on its expression level 14, 15 and on the strength of CD95 receptor stimulation. 16 Moderate expression of c-FLIP L was shown to promote apoptosis only upon strong receptor stimulation or in combination with overexpression of c-FLIP S or c-FLIP R . In contrast, high levels of c-FLIP L diminished the sensitivity for CD95-induced apoptosis and caspase-8 activation. 16 As numerous reports have demonstrated upregulation of c-FLIP in various cancers, prominently Hodgkin's lymphoma 17, 18 and melanoma, 4, 19 may allow tumours avoiding endogenous mechanisms inducing apoptosis and especially escaping immune surveillance. 2, 20, 21 Moreover, upregulation of c-FLIP has been suggested as a possible mechanism for resistance to therapeutic triggering of death receptors and the extrinsic apoptotic pathway, which is studied as a promising approach to cancer therapy. 22 In particular, the death receptor ligand TRAIL selectively induces apoptosis in various tumour cells in vivo without affecting cells in normal tissues. 23, 24 However, more recent studies described resistance against TRAIL-induced apoptosis in many primary tumour cells.
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CD95 and TRAIL have also been implicated in the pathogenesis and response to therapy in bladder cancer. 25, 26 In 2010, cancer of the urinary bladder was the fourth most common cancer in men in the United States as well as in the European Union (EU) and more than 90% of the cases were of the urothelial carcinoma histological subtype. Bladder cancer is primarily treated by surgery. Immunotherapy by BCG is commonly used to prevent recurrences and is thought to be mediated partly by effects of neutrophil-derived TRAIL on residual tumour cells. 27 Cisplatin-based chemotherapy is used for the treatment of advanced stage cases, but is only moderately efficacious. In 2008, almost 30 000 patients died of bladder cancer in the EU. Because of the high morbidity and mortality of bladder cancers, there is an urgent need for improved treatment strategies and in particular, for understanding the mechanisms underlying resistance to immunotherapy and chemotherapy.
The expression and function of c-FLIP in urothelial cancer are of obvious interest in that context, but few studies are available to date. One immunohistochemical study described an association of strong c-FLIP expression with tumour progression in bladder cancer, but curiously a lack of expression in normal urothelium. 28 As many cancers retained CD95 expression, the authors suggested that c-FLIP might contribute to resistance against CD95-induced apoptosis. However, no functional experiments were performed. In contrast, another study provided evidence that c-FLIP L might contribute to TRAIL resistance of some urothelial carcinoma cell lines. 29 Unfortunately, these studies have not been followed up to date. In particular, the contribution of the different c-FLIP isoforms to protection of CD95-and TRAILmediated apoptosis in urothelial carcinoma cells has not been studied. Therefore, we examined the expression of c-FLIP L and c-FLIP S in primary tumours and cell lines and their contribution to resistance against death receptor-mediated apoptosis in urothelial carcinoma cell lines in detail. Surprisingly, we observed that c-FLIP L was decreased in primary tumours and cell lines compared with normal urothelial tissue and cells. Nevertheless, urothelial carcinoma cell lines were resistant towards apoptosis-induction by CD95L or TRAIL, and required prevention of protein synthesis for sensitisation, indicating that short-lived proteins such as c-FLIP may contribute to resistance. Indeed, specific downregulation of c-FLIP by RNA interference using short hairpin RNAs (shRNAs) sensitised urothelial carcinoma cell lines towards both CD95-and TRAIL-mediated apoptosis. Thus, despite diminished expression, c-FLIP proteins appear to remain important resistance factors with respect to apoptosis-based therapies in bladder cancer.
Results
c-FLIP L expression is decreased in urothelial carcinoma. We first analysed the expression of c-FLIP L and c-FLIP S mRNA in urothelial carcinoma samples. c-FLIP L mRNA levels were moderately but significantly decreased in tumour samples compared with normal urothelial tissue (Figure 1a) . Similarly, the expression of c-FLIP L as quantified by real-time PCR was lower in urothelial carcinoma cell lines than in cultured normal urothelial cells (NUCs, Figure 1b) . c-FLIP S were not differentially expressed between either tissues or cell lines (Figures 1a and b) . Of note, a few tissue samples did not express c-FLIP S at all, most likely due to the presence of a functional SNP (rs10190751 A/G) in the c-FLIP gene, which determines whether c-FLIP R or FLIP S is produced. 6 In the context of the former study, 6 however, we had not observed significant changes in the distribution of this SNP between bladder cancer patients and controls (data not shown).
To find a suitable cell model for determining whether even lower levels of c-FLIP can mediate resistance towards death receptor-mediated apoptosis and to investigate the role of c-FLIP splice variants in urothelial carcinoma, we next analysed the urothelial carcinoma cell lines 639v, SD, 647v, VMCub1, BFTC905 and J82 for c-FLIP protein expression. Both protein isoforms, c-FLIP L and c-FLIP S , were readily observed in these cell lines except for 639v cells, in which c-FLIP S was hardly detectable (Figure 1c) . Furthermore, the cell lines were analysed by flow cytometry analysis and western blotting to evaluate death receptor expression (Supplementary Figure 1 ), sensitivity towards CD95L-induced apoptosis (data not shown), and the expression of proteins involved in the 'extrinsic' and 'intrinsic' apoptotic pathways (Supplementary Figure 2 ). The cell lines VMCub1 and SD were chosen for further experiments based on their death receptor and c-FLIP expression profile.
Cycloheximide (CHX) sensitises urothelial carcinoma cell lines towards CD95L-and TRAIL-induced apoptosis. To investigate whether the extrinsic pathway can be triggered in VMCub1 and SD, the death receptor expression of these cell lines was analysed by surface staining of the death receptors CD95, TRAIL-R1 (DR4), TRAIL-R2 (DR5) and TNF-R1. VMCub1 cells had a moderate-to-high expression of CD95, TRAIL-R2 and TNF-R1, whereas SD cells had a moderate-to-high expression of all the four death receptors (Figure 1d the absence or presence of CHX, followed by western blot analysis to examine caspase cleavage as an early event during apoptosis. There was only minimal cleavage of caspase-8 and caspase-3 after stimulation with CD95L or TRAIL alone, whereas the presence of CHX caused substantial cleavage of both caspases. Taken together, our results indicate that short-lived proteins have an important role in protecting the urothelial carcinoma cells against apoptosis. In particular, at least one short-lived protein protects against apoptosis at a step before caspase-8 activation, for which c-FLIP is the most likely candidate. 30, 31 c-FLIP overexpression protects urothelial carcinoma cells against apoptosis. To ensure that c-FLIP is indeed a short-lived protein in urothelial carcinoma cells, we followed protein levels of c-FLIP after treatment of VMCub1 and SD cells with CHX ( Figure 3a) . Consistent with previous reports, 30 ,31 a rapid turnover of both c-FLIP L and c-FLIP S was observed, with c-FLIP L being slightly more stable. This finding suggests that the c-FLIP proteins are likely candidates for the short-lived proteins responsible for the reduced sensitivity against apoptosis in the urothelial carcinoma cell lines. As it is known that all three c-FLIP splice variants can inhibit death receptor-mediated apoptosis, 3, 5, 32 we investigated whether overexpression of any c-FLIP isoform could protect VMCub1 and SD cells against apoptosis. The three c-FLIP splice variants c-FLIP L , c-FLIP S and c-FLIP R were cloned into a vector, which allows tracking of transfected cells by IRES-driven GFP expression. The generated constructs were first transiently transfected into 293T cells to verify that the respective c-FLIP variants and in addition GFP were expressed at the protein level (Figure 3b ). We then transiently transfected VMCub1 and SD cells with either the empty vector or one of the c-FLIP constructs, stimulated the cells with CD95L and examined the intracellular levels of active caspase-3 by flow cytometry. Indeed, both VMCub1 (Figures 3c and d ) and SD cells (Figures 3e and f) were protected by overexpression of any c-FLIP variant against CD95L-mediated apoptosis. The protective effect of c-FLIP overexpression was also confirmed by staining of transfected and stimulated cells using tetramethylrhodamine ethyl ester (TMRE; data not shown).
Knockdown of c-FLIP sensitises urothelial carcinoma cells for CD95L-induced apoptosis. As high expression of Figure 3) . The knockdown of c-FLIP L was less efficient than the c-FLIP S and c-FLIP L/S knockdowns. Still, we observed more efficient shRNA knockdowns in the urothelial cell lines VMCub1 and SD than in the human T-cell line CEM. 33 As assessed by measurement of DNA fragmentation, stimulation of VMCub1 and SD knockdown cells with increasing concentrations of CD95L led to elevated levels of apoptosis in the c-FLIP L/S double knockdown cells (Figures 4a  and b) . The effect was most prominent for the SD cells expressing shRNAs targeting both c-FLIP L and c-FLIP S , where the extent of apoptosis was comparable to those of wild-type SD cells treated with CHX (Figure 2a ). This finding strongly supports the argument that c-FLIP is a prominent short-lived anti-apoptotic protein in these cells. Moreover, SD cells with knockdown of c-FLIP L alone were highly susceptible towards CD95L-induced apoptosis, whereas SD cells with knockdown of c-FLIP S alone remained resistant (Figure 4b (Figure 5d ). In contrast, both caspases remained uncleaved in VMCub1 and SD cells stably transduced with scramble shRNAs, suggesting that c-FLIP proteins confer broad resistance to death receptor activation in urothelial carcinoma.
Discussion
Resistance to cell death is one hallmark of cancer cells. 1 Accordingly, proapoptotic factors such as Bax are often downregulated in tumours, whereas anti-apoptotic molecules such as Bcl-2, Bcl-x L or IAPs tend to be upregulated. Similarly, high c-FLIP expression has been observed in various cancers, for example, in Hodgkin's lymphoma 17, 18 and melanoma. 4 It is therefore intriguing that we observed a lower expression of the c-FLIP L isoform in urothelial tumour tissues compared with normal tissues, which was recapitulated in frequency and extent in urothelial carcinoma cell lines compared with NUCs. To our knowledge, there is only one previous study of c-FLIP expression in bladder cancer tissues, which was performed by immunohistochemistry. 28 These authors observed c-FLIP expression in 81% of 53 studied urothelial cancers, predominantly in cases with higher T-stage and worse clinical course. It is bit curious that c-FLIP could not be detected in 20% of the cancers and normal urothelium by immunohistochemistry in this study, as in our hands c-FLIP protein and its according mRNA was detectable in all carcinoma cell lines and in NUCs. Interestingly, in the study by Korkolopoulou et al., 28 concurrent expression of CD95, CD95L and c-FLIP was observed in 22 cases, suggesting a function of c-FLIP in protecting the tumours against CD95-mediated apoptosis. Our present study provides direct evidence for this function. Specific downregulation of c-FLIP by RNA interference using shRNAs sensitised urothelial carcinoma cell lines towards both CD95L-and TRAILmediated apoptosis. Consistently, a function of c-FLIP in resistance to TRAIL has been observed by others. 29 Although independent studies on c-FLIP mRNA and protein expression in tissue samples may be helpful, it will likely remain difficult to distinguish the different c-FLIP isoforms in tissue samples by immunohistochemistry. Our finding that they are differentially expressed in urothelial carcinoma accentuates the question as to their individual function. The two splice variants c-FLIP L and c-FLIP S inhibit death receptormediated apoptosis by different mechanisms 12 and can even have opposing functions on cell death. 15, 16 In contrast to lymphoid cells, in which c-FLIP S has a dominant role in protection against CD95-mediated apoptosis, 33 our data suggest that the short isoform has a more auxiliary function in urothelial carcinoma. In the SD model system, isoformspecific knockdown of c-FLIP L was sufficient to sensitise cells for apoptosis induction by death ligands. Importantly, knockdown of both isoforms in SD cells resulted in similar apoptosis levels as co-treatment with CHX, suggesting that c-FLIP is the major short-lived anti-apoptotic protein in these cells. In VMCub1 cells, however, single knockdowns did not sensitise for apoptosis and complete inhibition of c-FLIP expression resulted in partial sensitisation compared with CHX co-treatment, indicating that additional factors contribute to apoptosis resistance in this cell line. Of note, we detected elevated expression of Bcl-2 and Bcl-x L in VMCub1 cells, which may contribute to resistance against death receptormediated apoptosis.
Our observation that c-FLIP L is downregulated in urothelial carcinoma appears counterintuitive at first as one would expect that high expression of an anti-apoptotic molecule is generally beneficial for tumour cell survival. However, apart from apoptosis induction, signalling through CD95 exerts additional functions, especially in resistant cells. Thus, CD95 in some instances promotes tumour growth as well as motility and invasiveness of tumour cells. 34, 35 These functions are mediated by activation of the NF-kB and JNK pathways, which have been shown to be inhibited by high c-FLIP expression. 34, 36, 37 Therefore, cancer cells may have to fine-tune c-FLIP expression to balance apoptosis resistance on the one hand with non-apoptotic death receptor signalling via NF-kB and other pathways on the other hand. Moreover, c-FLIP L has been shown to have a dual role in apoptosis signalling being anti-apoptotic at high expression levels and proapoptotic at low expression levels. 16 Even more complicated, c-FLIP L acquires proapoptotic function in the presence of high c-FLIP S expression. Thus, as they also express c-FLIP S , urothelial carcinoma cells may benefit from downregulation of c-FLIP L by preventing its proapoptotic activity. Finally, an optimal c-FLIP L and c-FLIP S expression level and ratio may be required to prevent activation of the Ripoptosome, a recently described cell death-initiating multiprotein complex. 38, 39 Depending on its molecular composition, the Ripoptosome initiates either apoptosis or necroptosis. Activation of the kinases RIP1 and RIP3 leads to necroptosis, whereas their inactivation by caspase-8-mediated cleavage favours apoptosis. Importantly, c-FLIP S inhibits caspase-8 activity within the Ripoptosome and may, therefore, promote necroptosis. 38 In contrast, caspase-8 and c-FLIP L inhibit necroptosis, a cell death mode, which leads to inflammation. As the recruited inflammatory cells may result in tumour cell elimination, blocking Ripoptosome function by c-FLIP L may be important for urothelial carcinoma development.
Taken together, we have shown that c-FLIP, and in particular the c-FLIP L splice variant, is an important apoptosis resistance factor in urothelial carcinomas. Therefore, targeting c-FLIP in CD95L-or TRAIL-based therapies may be a promising approach to treat urothelial tumours. Moreover, c-FLIP may constitute a factor in the development of resistance against immunotherapy and chemotherapy used in the treatment of bladder cancer, in so far as their efficacy depends on activation of death receptors.
Materials and Methods
Patients and tissue samples. Tissue samples were obtained from patients undergoing cystectomy for urothelial carcinoma at the Department of Urology of the Heinrich-Heine-University Duesseldorf between 1995 and 2004. Twenty-four patients were male and seven were female; average age at surgery was 69.9 years (range 54-94 years). The samples were selected to comprise all stages and included three tumours each staged as pTa or pT1, 5 staged as pT2, 11 staged as pT3 and 7 staged as pT4. Lymph node metastases were present in seven patients. The lymph node status was not determined further for two additional patients with 4pT2 cancers. Eleven cancers were graded as G2 and 20 as G3. Morphologically normal tissue from 10 patients was used for comparison. The use of patient tissues was approved by the Ethics Committee of the Medical Faculty of the Heinrich-Heine-University Duesseldorf.
Cell culture and transient transfections. Urothelial carcinoma cell lines 639v, SD, 647v, VMCub1, BFTC905 and J82 as well as human embryonic kidney cells (293T) were cultured in Dulbecco's modified Eagle's medium (DMEM high glucose; Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal calf serum (PAA Laboratories, Coelbe, Germany) and 50 mg/ml of each penicillin and streptomycin (Invitrogen). Transient transfections of 293T, VMCub1 and SD cells were performed with JetPEI (Polyplus transfection, Illkirch, France) or Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's instructions. Normal urothelial cells were isolated and cultured according to the method of Southgate et al. with slight modifications as described. 40 Lentiviral infection of cells. c-FLIP MISSION TRC shRNA Target Set cloned into the lentiviral vector pLKO.1 was purchased from Sigma (Sigma-Aldrich Chemie, Steinheim, Germany). Generation of c-FLIP short shRNA was previously described. 33 Lentiviral vectors were co-transfected with the envelope vector pMD2.G (Addgene no. 12259) and the gag-pol expression plasmid pCMV_dR8.2dvpr (Addgene no. 8455) into 293T cells as described in 'Cell culture and transient transfections'. Lentiviruses (LVs) were collected 36 and 60 h after transfection. Crude virus was filtered through 0.45 mm PVDF filters (Millipore, Billerica, MA, USA), concentrated by ultracentrifugation at 100 000 Â g for 60 min at 41C and stored at À801C until further use. Titres were determined by infection of HeLa cells with serial dilutions of LV stocks and 5 mg/ml polybrene (Sigma-Aldrich Chemie). Specific knockdown of the various c-FLIP isoforms was verified by western blot analysis. SD and VMCub1 cells were infected by adding LVs and 5 mg/ ml polybrene to 2 Â 10 6 cells. Cells were centrifuged for 1 h at 860 g and then incubated over night. Stably transfected clones were selected by limited dilution in medium containing 4 mg/ml puromycin (Sigma-Aldrich Chemie).
Cloning of c-FLIP L , c-FLIP S and c-FLIP R . c-FLIP L , c-FLIP S and c-FLIP R were cloned using previously described plasmids 3, 6 as PCR templates. PCR reactions were performed with Phusion -flash proofreading polymerase (Finnzymes, Western blot analysis. For western blot analysis, cells were lysed in TPNE buffer (PBS adjusted to 300 mM NaCl, 1% Triton-X100, 2 mM EDTA, 1 mM PMSF and 1 mg/ml each of leupeptin, aprotinin, chymostatin and pepstatin A). Twenty micrograms of postnuclear supernatant protein as determined by the BCA method (Pierce Biotechnology, Rockford, IL, USA) were separated by 12% SDS-PAGE, blotted onto a PVDF membrane (Amersham, Freiburg, Germany) and blocked with 5% non-fat dry milk in TBS/Tween (0.05% Tween-20 in TBS). The blots were washed with TBS/Tween and were thereafter incubated with specific antibodies overnight at 41C. The following day, blots were washed with TBS/Tween, incubated with horseradish peroxidase-coupled secondary antibodies (1 : 20 000) for 1 h at room temperature, washed again and developed with a chemiluminescence reagent (Pierce Biotechnology). For stripping, blots were incubated in Re-Blot mild solution (Millipore) according to the manufacturer's protocols.
The antibodies used for western blotting were b-actin (AC-74; Sigma-Aldrich Chemie), caspase-3 (CPP32; R&D Systems, Minneapolis, MN, USA), Flow cytometry assays. Cell surface staining and cytotoxicity assays were performed as described previously. 30 For assaying apoptosis, 2.5 Â 10 5 cells per well were left untreated or were stimulated in 6-well-plates for 16 h with CD95L or for 24 h with TRAIL at the indicated concentrations. The following antibodies were used for cell surface staining: TNF-R1 (kind gift of Dr. H Wajant, Wuerzburg, Germany), TRAIL-R1 (Enzo Life Sciences) and TRAIL-R2 (PE-conjugated; eBioscience, San Diego, CA, USA). CD95 surface staining was performed with 2R2 antibody (kind gift of Dr. K Schulze-Osthoff). TNF-R1, TRAIL-R1 and CD95 antibodies were labelled with PE-conjugated goat-anti-mouse secondary antibody (Jackson ImmunoResearch, Suffolk, UK). For assaying the effect of c-FLIP overexpression on apoptosis sensitivity, VMCub1 and SD cells were transiently transfected (2.5 Â 10 5 cells in 6-well-plates) with empty pIRES2EGFP vector (Clontech) or the c-FLIP L , c-FLIP S , c-FLIP R constructs (see above). Cells were left untreated or were stimulated with 1 ng/ml CD95L for 4 h, followed by intracellular staining of active caspase-3 (BD Biosciences) or TMRE staining (Enzo Life Sciences) according to the manufacturer's manual.
Statistical analysis. All statistical analyses were performed by nonparametric Mann-Whitney U-tests to determine statistical significance using GraphPad Prism (Graph-Pad-Software Inc., La Jolla, CA, USA). Standard deviation and standard error of the mean were used as error bars.
